Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)30.49
  • Today's Change0.21 / 0.69%
  • Shares traded6.97m
  • 1 Year change-73.70%
  • Beta1.8250
Data delayed at least 15 minutes, as of Jul 03 2025 18:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).

  • Revenue in USD (TTM)3.18bn
  • Net income in USD-3.36bn
  • Incorporated2016
  • Employees5.80k
  • Location
    Moderna Inc325 BINNEY STREETCambridge 02142United StatesUSA
  • Phone+1 (617) 714-6500
  • Fax+1 (617) 583-1998
  • Websitehttps://www.modernatx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ionis Pharmaceuticals Inc717.25m-458.03m6.84bn1.07k--14.38--9.54-2.99-2.994.692.990.25720.504231.99670,956.10-16.43-11.71-18.33-13.7298.5398.42-63.86-44.159.62--0.7245---10.48-8.88-23.92--7.94--
Revolution Medicines Inc0.00-697.51m7.05bn616.00--3.39-----3.99-3.990.0011.160.00----0.00-32.64-28.38-34.69-30.68-------1,324.37----0.00---100.00---37.52--31.83--
Charles River Lbrtrs ntrntl Inc4.02bn-31.56m7.72bn18.60k--2.4220.671.92-0.65-0.6578.3365.040.51138.075.21216,268.70-0.29635.12-0.34246.0134.6936.56-0.57969.471.163.810.43680.00-1.929.09-97.83-47.2510.64--
Blueprint Medicines Corp562.12m-155.73m8.30bn682.00--24.22--14.77-2.46-2.468.775.300.50320.9018.04866,132.50-13.94-23.15-17.53-26.8296.4896.65-27.70-75.502.75--0.5313--104.0450.2286.77---19.87--
BIO-TECHNE Corp1.21bn131.65m8.33bn3.10k64.774.1334.356.890.82040.82047.5412.870.45062.195.20389,925.504.919.425.2210.0466.3967.2910.8921.412.5846.270.140522.791.9710.17-41.0711.8619.870.00
Medpace Holdings Inc2.16bn416.39m9.24bn5.90k24.5416.1220.744.2813.1013.1067.7919.941.17--7.47365,522.0022.5516.4051.5929.7731.5129.5119.3116.75----0.000.0011.8419.6243.0732.1915.33--
Exact Sciences Corp2.83bn-1.02bn10.07bn6.90k--4.20--3.56-5.50-5.5015.2612.710.4685.7410.87409,873.60-16.87-11.29-18.71-12.3869.0271.21-36.06-30.902.38-173.160.494--10.3725.78-403.97--0.9474--
Tempus AI Inc803.32m-721.31m10.55bn2.40k--32.34--13.14-7.79-7.795.491.890.79848.554.34334,714.60-70.47-53.69-96.71-72.1057.0945.68-88.27-84.291.56-13.530.7106--30.3862.05-180.61--5.36--
Regencell Bioscience Holdings Ltd0.00-4.09m11.37bn12.00--1,692.87-----0.0083-0.00830.000.01360.00----0.00-44.90-56.31-44.90-77.51------------0.00------26.73------
Moderna Inc3.18bn-3.36bn11.79bn5.80k--1.17--3.71-8.71-8.718.1726.010.21594.7029.55547,758.60-22.8113.72-26.3818.7668.6876.34-105.6723.744.14--0.00620.00-52.75121.8624.46--101.61--
ICON PLC8.19bn758.19m11.93bn41.25k16.331.269.991.469.199.1999.32119.560.4852--3.01195,528.004.493.705.394.4629.0829.009.257.41--5.820.2647--1.9924.1729.2616.1827.11--
Exelixis Inc2.30bn643.57m12.59bn1.15k20.945.9618.695.472.202.207.887.750.81513.238.802,004,291.0022.829.5126.4410.7796.7896.3227.9915.613.44--0.000.0018.4917.51150.8910.1817.25--
Data as of Jul 03 2025. Currency figures normalised to Moderna Inc's reporting currency: US Dollar USD

Institutional shareholders

38.86%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 202538.87m10.07%
Baillie Gifford & Co.as of 31 Mar 202524.95m6.47%
Fidelity Management & Research Co. LLCas of 31 Mar 202520.30m5.26%
BlackRock Fund Advisorsas of 31 Mar 202517.87m4.63%
SSgA Funds Management, Inc.as of 31 Mar 202517.78m4.61%
Geode Capital Management LLCas of 31 Mar 20257.46m1.93%
Th�l�me Partners LLPas of 31 Mar 20257.24m1.88%
D. E. Shaw & Co. LPas of 31 Mar 20255.64m1.46%
Invesco Capital Management LLCas of 31 Mar 20255.39m1.40%
Two Sigma Investments LPas of 31 Mar 20254.45m1.15%
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.